Use of Cardiovascular Disease Secondary Prevention Medications in Four Middle East Countries in a Community Setting
The use of secondary prevention medication is low in ME and has not reached the modest recommended WHO target of 50% use of 3 or more medications. Independent factors of higher use were, better socioeconomic status (household wealth, country wealth and education) and better contact and accessibility to health care (increasing age, female gender, obesity, diabetes and hypertension).
Authors
- Ahmad Bahonar (ORCID: https://orcid.org/0000-0002-8561-900X)
- Hamda Khansaheb (ORCID: https://orcid.org/0000-0002-7129-1138)
- Mostafa Al Shamiri
- Salim Yusuf (ORCID: https://orcid.org/0000-0003-4776-5601)
- Marwan Zidan (ORCID: https://orcid.org/0000-0002-8646-162X)
- Mariam AlShamsi
- A Rais
- Roya Kelishadi (ORCID: https://orcid.org/0000-0001-7455-1495)
- Khalid F. AlHabib (ORCID: https://orcid.org/0000-0002-6692-3874)
- Noushin Mohammadifard (ORCID: https://orcid.org/0000-0003-1776-1060)
- Sumathy Rangarajan (ORCID: https://orcid.org/0000-0003-2420-5986)
- Afzalhussein Yusufali (ORCID: https://orcid.org/0000-0003-3378-2646)
- Rasha Khatib (ORCID: https://orcid.org/0000-0002-8046-9559)
- Afra Khalid Bintouq
Institutions
- Isfahan University of Medical Sciences (IR)
- Aurora Health Care (US)
- Dubai Health Authority (AE)
- King Saud University (SA)
- Population Health Research Institute (CA)
- Zanzibar University (TZ)
- Hamilton Health Sciences (CA)
- McMaster University (CA)
Publication Details
- Journal
- Global Heart
- Published
- 2024-08-26
- DOI
- https://doi.org/10.5334/gh.1349
- Citations
- 2
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Heart and Stroke Foundation of Canada
- International Development Research Centre
- Ontario Ministry of Health and Long-Term Care
- King Saud University
- Saudi Heart Association
- Servier
- Canadian Institutes of Health Research